Post COVID and Apheresis - Where are we Standing?
Horm Metab Res
; 54(11): 715-720, 2022 Nov.
Статья
в английский
| MEDLINE | ID: covidwho-2096875
ABSTRACT
A continual increase in cases of Long/Post COVID constitutes a medical and socioeconomic challenge to health systems around the globe. While the true extent of this problem cannot yet be fully evaluated, recent data suggest that up to 20% of people with confirmed SARS-CoV-2 suffer from clinically relevant symptoms of Long/Post COVID several weeks to months after the acute phase. The clinical presentation is highly variable with the main symptoms being chronic fatigue, dyspnea, and cognitive symptoms. Extracorporeal apheresis has been suggested to alleviate symptoms of Post/COVID. Thus, numerous patients are currently treated with apheresis. However, at present there is no data from randomized controlled trials available to confirm the efficacy. Therefore, physicians rely on the experience of practitioners and centers performing this treatment. Here, we summarize clinical experience on extracorporeal apheresis in patients with Post/COVID from centers across Germany.
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
Blood Component Removal
/
COVID-19
Тип исследования:
Экспериментальные исследования
/
Прогностическое исследование
/
Рандомизированные контролируемые испытания
Темы:
Длинный Ковид
Пределы темы:
Люди
Страна как тема:
Европа
Язык:
английский
Журнал:
Horm Metab Res
Год:
2022
Тип:
Статья
Аффилированная страна:
A-1945-9694
Документы, близкие по теме
MEDLINE
...
LILACS
LIS